Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 3/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 3/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CD69 | Q07108 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25970258 | 0.80 | LGALS3 (0.42) | LGALS3LGALS7; LGALS7BLGALS9LGALS1POLB | |
| SCHEMBL24635181 | 0.79 | LGALS3 (0.42) | LGALS3LGALS7; LGALS7BLGALS9LGALS1POLB | |
| SCHEMBL25963114 | 0.73 | LGALS3 (0.38) | LGALS3LGALS7; LGALS7BLGALS9LGALS1POLB | |
| SCHEMBL25970268 | 0.73 | LGALS3 (0.38) | LGALS3LGALS7; LGALS7BLGALS9LGALS1POLB | |
| SCHEMBL24478860 | 0.73 | LGALS3 (0.38) | LGALS3LGALS7; LGALS7BLGALS9LGALS1POLB | |
| SCHEMBL23322296 | 0.72 | LGALS3 (0.37) | LGALS3LGALS7; LGALS7BLGALS9LGALS1CA1 | |
| SCHEMBL24478872 | 0.72 | LGALS3 (0.38) | LGALS3LGALS7; LGALS7BLGALS9LGALS1POLB | |
| SCHEMBL23280950 | 0.71 | LGALS8 (0.48) | LGALS3LGALS7; LGALS7BLGALS9LGALS1 | |
| SCHEMBL23603141 | 0.69 | MAPK1 (0.52) | LGALS3LGALS7; LGALS7BLGALS1POLBCD69 | |
| SCHEMBL21077729 | 0.69 | MAPK1 (0.52) | LGALS3LGALS7; LGALS7BLGALS1POLBCD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259254-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | TAMBO, INC. | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259254-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | TIE1, CD74, MERTK | LGALS3 350/4885LGALS7; LGALS7B 336/4885LGALS9 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.